HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and foreign trade business. It has established a "1+2+3+4=1" service system and can supply L-Leucine sourced directly from multiple well-known original manufacturers.
As a foreign trade service provider with independent R&D capabilities, HiSiaddi has repeatedly proposed L-Leucine formula optimization solutions and application improvement suggestions through technological transformation cooperation with manufacturers and precise insight into market demands. Below is a case study of HiSiaddi’s L-Leucine formula optimization consulting service.
Please contact HiSiaddi customer service if you require more formula optimization consulting services.
The purchasing party in this cooperation is NUTRILAB Lyon, a clinical nutrition company headquartered in Lyon, France. With 28 years of experience focusing on three major categories: high-end postoperative enteral nutrition, medical sustained-release capsules and high-end sports nutrition stock solutions across France, Belgium and the Netherlands, its products are supplied to clinical nutrition departments of top-tier public tertiary hospitals in France, high-end organic pharmacy chains in Western Europe and exclusive nutrition supply chains for professional football clubs in Europe. All finished products comply with the EP Pharmacopoeia, EU LFGB, EFSA raw material specifications and France’s AFNOR medical nutrition access standards, targeting postoperative rehabilitation patients, chronic disease dietary intervention groups and high-end competitive athletes. It ranks as a benchmark mid-to-high-end purchaser of amino acid raw materials in Europe.
The enterprise has long purchased pharmacopoeia-grade L-Leucine from Evonik (Germany) and Ajinomoto (Japan), with an annual stable total procurement volume of 36 tons. Triggered by raw material price hikes from overseas original manufacturers, raised minimum customized order quantities and extended ocean delivery cycles up to 90 days, it launched a domestic Chinese L-Leucine replacement procurement project in 2025. After putting the first batch of standard domestic EP-grade L-Leucine raw materials into mass production, four major mass production technical failures emerged consecutively: delamination and agglomeration of mixed nutritional powder, precipitation of floccules in oral liquids under low-temperature storage, deviated in-vitro dissolution curves of sustained-release capsules and excessive browning of finished products during long-term storage. Raw material manufacturers could only fine-tune indicators at the raw material purity level, lacking technical reserves for downstream formulation applications, and failed to resolve implementation problems from three dimensions: raw material physical properties, formula ratios and production processes. This forced intermittent shutdowns of the client’s three automated production lines, and two batches of pre-mixed semi-finished raw materials were scrapped, causing direct economic losses exceeding 92,000 Euros.
After raw material manufacturers proved incapable of addressing downstream application technical pain points, the client formally entrusted HiSiaddi. Leveraging its amino acid raw material physical and chemical database, terminal formulation application technology and domestic manufacturer process resources, HiSiaddi resolved technical obstacles one by one from three dimensions: raw material physical property improvement, formula ratio optimization and production line process adjustment, delivering adapted formulas and special-grade L-Leucine, and finalizing a framework order for annual procurement of 36 tons.
The client’s three finished product formula systems differ, and physical properties of standard domestic national standard EP-grade L-Leucine fail to match the terminal formula environment. Four major technical problems directly restricted mass production implementation, with detailed failure descriptions as follows:
The client’s enteral nutrition powder is compounded with whey protein, complex minerals and multiple amino acids. Standard domestic L-Leucine features polarized particle sizes: coarse crystals with D90＞95μm and ultrafine dust accounting for over 18%. Large particles settle at the bottom of powder while fine powder floats on the upper layer due to static electricity, and delamination persists even after high-speed automated mixing for 30 minutes. Meanwhile, the raw material exhibits high moisture absorption; agglomeration and caking occur after storage for 12 days under 58% relative humidity in the workshop, blocking automatic feeding screws during blanking and triggering frequent production line shutdowns for equipment cleaning. Domestic raw material manufacturers only guarantee content ≥98.5%, lacking supporting technologies for particle size regulation and anti-moisture absorption modification, unable to optimize powder bulk density and fluidity.
The sports oral liquid formula features a weakly acidic environment of pH 4.1~4.5, and finished products require full cold-chain storage and transportation (5~10°C). L-Leucine itself has weak water solubility, and the solubility of standard uncoated crystalline raw materials drops sharply under low temperatures, resulting in white floccules separating at the bottom of bottles after 15 days of warehousing, failing French beverage quality inspection standards. Raw material manufacturers only adjusted crystallization processes to improve purity, unable to enhance low-temperature solubility and compatibility with weak acid systems.
Medical sustained-release capsules adopt a hypromellose matrix formula. The client’s internal control requirements: dissolution ≤42% in gastric fluid within 4 hours, cumulative dissolution ≥90% in intestinal fluid within 8 hours. Standard L-Leucine crystals feature high porosity, causing rapid active ingredient release in gastric fluid; measured 4-hour dissolution exceeded 58%, with dissolution curves failing to meet EP Pharmacopoeia and French medical nutrition registration standards, barring finished products from sales channels of hospital pharmacies.
Powder and capsule finished products develop slight yellowing after storage for 60 days under normal temperature and light-shielded conditions. Testing confirmed the reaction between trace reducing sugars and free impurities in L-Leucine with lactose in the formula (Maillard reaction). Factory COA only labeled main content without controlling trace reducing impurities, and manufacturers lacked refined impurity removal processes to eliminate browning triggers at the source.
Four cooperating raw material manufacturers focused solely on raw material synthesis and mass production, prioritizing their own product indicators without understanding downstream formulation logic, only adjusting purity and refusing to cooperate in raw material modification and refined impurity control optimization, stalling the client’s formula improvement work.
HiSiaddi set up a special team consisting of raw material physical and chemical engineers, formulation application specialists and production process consultants. It first sampled and fully tested the client’s existing raw materials, finished product formulas and workshop production parameters to accurately locate root causes of failures, and collaborated with two leading domestic amino acid manufacturers equipped with clean modification sections and chromatographic refining equipment to implement targeted optimization across four modules, balancing raw material customization and minor terminal formula adjustments simultaneously.
1. Optimize crystallization processes at the raw material production end: adjust cooling rate and crystallization pH to generate near-spherical uniform crystal grains instead of traditional needle-shaped crystals. Adopt low-temperature classified airflow crushing to precisely lock the D90 range at 46~53μm, control ultrafine powder proportion below 6% and completely remove oversized particles, raising bulk density from 0.52g/ml to 0.71g/ml and improving powder mixing compatibility.
2. Dry micro-coating modification: add medicinal anhydrous calcium hydrogen phosphate for surface flow-aiding coating in GMP clean workshops to reduce raw material moisture absorption; moisture absorption weight gain ≤1.1% under 58% humidity for 72 hours, eliminating agglomeration from the source.
3. Minor formula adjustment: HiSiaddi guided the client to adjust feeding sequence in the pre-mixing process – pre-blend L-Leucine with a small amount of maltodextrin for dilution before adding to the main mixing tank to eliminate electrostatic agglomeration. After optimization, three consecutive pilot batches showed no delamination during powder mixing, with smooth automated feeding free of blockages.
1. Adopt low-temperature anhydrous alcohol system recrystallization in the raw material refining stage to reduce internal capillary pores of crystals, supplemented by surface coating with small amounts of food-grade polydextrose to enhance wettability in weak acid environments, raising raw material solubility by 32% at 8°C in pH 4.3 systems.
2. Minor formula optimization: HiSiaddi recommended the client adjust the buffer salt ratio of the system and add a small amount of sodium citrate to stabilize pH fluctuations, avoiding local sharp acid value drops triggering raw material precipitation. Pilot finished products remained clear without any precipitates or floccules after low-temperature storage for 90 days.
1. Customize dense L-Leucine with medium-high crystallinity to reduce internal crystal voids and slow dissolution rates in gastric fluid.
2. Simultaneously assist the client in fine-tuning auxiliary material ratios of capsule matrices and slightly raise the proportion of sustained-release blockers. After dual adjustment of raw materials and formulas, measured in-vitro dissolution indicators: 39.7% dissolution in gastric fluid within 4 hours, 92.3% cumulative dissolution in intestinal fluid within 8 hours, fully falling within the client’s pharmacopoeia control range and smoothly passing quality inspection verification by France’s AFNOR.
1. Add a secondary purification section using simulated moving bed chromatography at the production end to remove reducing sugars, trace aldehyde impurities within raw materials, controlling single unknown impurities ≤0.04%.
2. HiSiaddi guided the client to optimize the drying process of finished products, lowering residual moisture of finished products to below 3.2% and reducing conditions triggering Maillard reactions. Accelerated testing of finished products for 6 months showed no yellowing, with active ingredient attenuation ＜2.5%, meeting the EU three-year shelf life standard.
HiSiaddi coordinated production of 15kg of each of the three modified raw material grades, shipped via international cold chain to the client’s R&D laboratory in Lyon, France. The client conducted full-formulation pilot mass production, and all physical and chemical, stability and dissolution tests of powder, oral liquid and capsule finished products passed full compliance verification. The client issued a technical qualification confirmation letter to finalize fixed raw material specifications and matching improved formulas.
The annual total of 36 tons of raw materials was split into six batches by quarter for production scheduling, with allocated procurement volumes for the three modified grades: 15 tons for powder special grade, 11 tons for oral liquid modified grade, 10 tons for sustained-release capsule special grade. Before delivery of each batch, HiSiaddi coordinated third-party SGS full-index testing aligned with the EP Pharmacopoeia to issue Chinese-English bilingual COA, LFGB compliance documents and REACH import filing documents, while standardizing export moisture-proof packaging. Goods were shipped from Shanghai Port to Marseille Port in separate batches, all clearing customs and warehousing without incidents. After raw material delivery to production lines, the client’s three production lines resumed full-load mass production, the issue of scrapped semi-finished products was completely eliminated, and finished products maintained stable supply channels to public hospitals and high-end pharmacies across France.
1. The client fully phased out original imported L-Leucine from Germany and Japan, switching 100% of the annual 36 tons of raw materials to domestic modified grades. Comprehensive procurement costs decreased by 23.8%, and raw material delivery cycles were shortened from 90 days to 38 days, greatly improving supply chain stability.
2. The client’s Belgian subsidiary launched R&D of new low-nitrogen medical nutrition powder for kidney disease patients, entrusting HiSiaddi with full raw material selection and pre-stage technical debugging of formulas, adding annual procurement of 7.5 tons.
3. During the project initiation phase of the enterprise’s new children’s dietary amino acid oral liquid, HiSiaddi intervened in advance to predict raw material physical properties and preemptively avoid formula adaptation hidden risks.
The vast majority of domestic L-Leucine manufacturers focus on raw material synthesis and mass production, centering sales on national standard and EP standard off-the-shelf grades, only controlling raw material purity indicators without application R&D capacity for downstream formulation and terminal production processes. Mid-to-high-end European medical nutrition enterprises feature stringent formula systems restricted by pH, temperature, auxiliary material compatibility, storage and transportation conditions, and standard raw materials easily trigger implementation failures after mass production. Overseas purchasers lack familiarity with domestic raw material modification resources and technical paths, and independent procurement often falls into the dilemma of qualified raw materials yet failed finished product mass production.
Breaking the traditional foreign trade mindset of only supplying goods, HiSiaddi centers its services on three-dimensional technical support covering raw material physical properties, terminal formulas and production processes, bridging domestic manufacturer modification process resources and the client’s formula pain points to resolve implementation challenges comprehensively via raw material customization, minor formula adjustments and production optimization. It not only helps mid-to-high-end European clients realize localized procurement for cost reduction and efficiency improvement, but also assists high-quality domestic amino acid manufacturers in entering the supply chain of European high-end medical nutrition raw materials, achieving two-way win-win results for both supply and demand sides in technology and trade.
Please contact HiSiaddi customer service if you require more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
